Though the RNAi field was shaken in late 2010 and early 2011 by the decisions of two major pharmaceutical players to drop their in-house development of oligonucleotide medicines, industry insiders saw a modest renewal of big pharma's interest in the gene-silencing technology in 2012.

However, concerns that RNAi won't live up to its potential remain, making solid clinical demonstrations of its therapeutic utility and even regulatory approvals a must before it will be embraced as warmly as it had in previous years, they said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.